Analysis of microRNA expression in canine mammary cancer stem-like cells indicates epigenetic regulation of transforming growth factor-beta signaling

Journal of Physiology and Pharmacology

Volumn 66, Issue 1, 2015, Pages 29-37

  Rybicka, A ^a   Mucha, J ^a   Majchrzak, K ^a   Taciak, B ^a   Hellmen, E ^b   Motyl, T ^a   Krol, Magdalena ^a  

^a WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Cancer stem cells; Canine mammary cancer; MicroRNA; Transforming growth factor; Tumor necrosis factor beta

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CHUK PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MYOCYTE ENHANCER FACTOR 2; PEPTIDES AND PROTEINS; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SMAD2 PROTEIN; SOS PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL SELECTION; COCULTURE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE SEQUENCE; GENETIC EPIGENESIS; MICROARRAY ANALYSIS; NONHUMAN; OVERLAPPING GENE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CANCER STEM CELL; CELL LINE; DOG; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY; PHENOTYPE;

ANIMALS; CELL LINE; DATABASES, GENETIC; DOGS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOTYPE; MAMMARY NEOPLASMS, ANIMAL; MICRORNAS; NEOPLASTIC STEM CELLS; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84923196926     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58: 267-284.
2. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22: 457-472.
3. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008; 10: 1433-1443.
4. Shafee N, Smith CR, Wei S, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008; 68: 3243-3250.
5. Soltysik K, Czekaj P. Membrane estrogen receptors - is it an alternative way of estrogen action? J Physiol Pharmacol 2013; 64: 129-142.
6. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One 2013; 8: e67811.
7. Heidel FH, Bullinger L, Feng Z, et al. Genetic and pharmacologic inhibition of beta-catenin targets imatinibresistant leukemia stem cells in CML. Cell Stem Cell 2012; 10: 412-424.
8. Korbut E, Ptak-Belowska A, Brzozowski T. Mechanisms promoting physiological cells progression into tumorigenesis. J Physiol Pharmacol 2012; 63: 565-570.
9. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66: 6063-6071.
10. Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010; 70: 709-718.
11. Sachlos E, Risueno RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012; 149: 1284-1297.
12. Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 2010; 19: 27-32.
13. Barh D, Malhotra R, Ravi B, Sindhurani P. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 2010; 17: 70-80.
14. Hellmen E. Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines. In Vitro Cell Dev Biol 1992; 28A: 309-319.
15. Hellmen E, Moller M, Blankenstein MA, Andersson L, Westermark B. Expression of different phenotypes in cell lines from canine mammary spindle-cell tumours and osteosarcomas indicating a pluripotent mammary stem cell origin. Breast Cancer Res Treat 2000; 61: 197-210.
16. Van Leeuwen IS, Hellmen E, Cornelisse CJ, Van den Burgh B, Rutteman GR. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res 1996; 16: 3737-3744.
17. Krol M, Pawlowski KM, Skierski J, et al. Transcriptomic "portraits" of canine mammary cancer cell lines with various phenotypes. J Appl Genet 2010; 51: 169-183.
18. Krol M, Mucha J, Majchrzak K, et al. Macrophages mediate a switch between canonical and non-canonical Wnt pathways in canine mammary tumors. PLoS One 2014; 9: e83995.
19. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-2319.
20. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
22. Brinkhof B, Spee B, Rothuizen J, Penning LC. Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 2006; 356: 36-43.
23. Etschmann B, Wilcken B, Stoevesand K, von der Schulenburg A, Sterner-Kock A. Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. Vet Pathol 2006; 43: 934-942.
24. Skidan I, Steiniger SC. In vivo models for cancer stem cell research: a practical guide for frequently used animal models and available biomarkers. J Physiol Pharmacol 2014; 65: 157-169.
25. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 2008; 8: 784-804.
26. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 2009; 69: 8555-8562.
27. Ferletta MJ, Grawe J, Hellmen E. Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int J Dev Biol 2011; 55: 791-799.
28. Pang LY, Cervantes-Arias A, Else RW, Argyle DJ. Canine mammary cancer stem cells are radio- and chemo- resistant and exhibit an epithelial-mesenchymal transition phenotype. Cancers (Basel) 2011; 3: 1744-1762.
29. Magalhaes GM, Terra EM, de Oliveira Vasconcelos R, et al. Immunodetection of cells with a CD44+/CD24– phenotype in canine mammary neoplasms. BMC Vet Res 2013; 9: 205.
30. Michishita M, Akiyoshi R, Suemizu H, et al. Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines. Vet J 2012; 193: 508-513.
31. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L Brca1 breast tumors contain distinct CD44+/CD24– and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10: R10.
32. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
33. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
34. Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells. Int J Mol Sci 2013; 14: 14712-1423.
35. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29: 4194-4204.
36. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
37. Zhu Y, Yu F, Jiao Y, et al. Reduced miR-128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi- 1 and ABCC 5. Clin Cancer Res 2011; 17: 7105-7115.
38. Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Res 2010; 12: 210.
39. Tang W, Yu FF, Yao H, et al. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 2014; 33: 2629-2638.
40. Hu Y, Zhu Q, Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS One 2014; 9: e92099.
41. Chiang CH, Hou MF, Hung WC. Up-regulation of miR- 182 by beta-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta 2013; 1830: 3067-3076.
42. Butz H, Racz K, Hunyady L, Patocs A. Crosstalk between TGF-beta signaling and the microRNA machinery. Trends Pharmacol Sci 2012; 33: 382-393.
43. Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 2010; 124: 89-99.
44. Gal H, Pandi G, Kanner AA, et al. MIR-451 and Imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem Biophys Res Commun 2008; 376: 86-90.
45. Wang Y, Yu Y, Tsuyada A, et al. Transforming growth factorbeta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011; 30: 1470-1480.
46. Watabe T. Miyazono K. Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res 2009; 19: 103-115.
47. Bhola NE, Balko JM, Dugger TC, et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013; 123: 1348-1358.